Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Neoadjuvant RCT Versus CT for Patients With Locally Advanced Potentially Resectable Adenocarcinoma of the GEJ

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone fr patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)

neutrophil count
renal function
intrauterine device (iud)
flot
flot regimen
  • 0 views
  • 05 Aug, 2020
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients. Correlative studies on tumor and blood samples could identify potential biomarkers of efficacy and help defining personalized treatment strategy.

adjuvant chemotherapy
stage iv colorectal cancer
liver metastasis
adjuvant
metastatic colorectal cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin …

neutrophil count
hepatitis b
HIV Infection
metastasis
flot regimen
  • 0 views
  • 05 Aug, 2020
FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Patients with metastatic adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations . One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin (FOLFOX6), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Irinotecan (mFOLFIRINOX).

gastric carcinoma
neutrophil count
hepatitis b
carcinoma
HIV Infection
  • 0 views
  • 16 Feb, 2024
  • 1 location
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or …

esophageal cancer
x-rays
neutrophil count
pathologic stage iv gastric cancer ajcc v8
major surgery
  • 0 views
  • 16 Feb, 2024
  • 255 locations
Neo-TACE-HAIC for BCLC B Stage HCC (Neoconcept)

However, a relative high recurrence risk leads surgeons to investigate the value of preoperative treatment. Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for unresectable HCC. Pilot study showed TACE combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.

folfox regimen
oxaliplatin
hepatic arterial infusion
carcinoma
liver cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Patients will be included following inclusion/exclusion criteria in a prospective, non-randomized, open label, single arm phase II study to receive 6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks …

vascular invasion
diverticulosis
diarrhea
adenocarcinoma of rectum
neutrophil count
  • 0 views
  • 16 Feb, 2024
  • 10 locations
Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer

The phase III FOWARC trial, compared neoadjuvant therapy with and without radiation and found that perioperative mFOLFOX6 alone led to a similar downstaging rate as fluorouracil-radiotherapy, and no significant difference in outcomes was found between mFOLFOX6 without radiotherapy and 5-FU- radiotherapy.

total mesorectal excision
adjuvant
metastatic colorectal cancer
progressive disease
renal function
  • 0 views
  • 16 Feb, 2024
  • 1 location
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

cisplatin
nasopharyngeal carcinoma
karnofsky performance status
renal function test
carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population

This is an observational research study. Patients with rectal cancer can choose different courses of treatment. This study will follow these patients over the course of approximately six years, depending on their treatment. Patients will be monitored through clinic visits and survey assessments to see how they do, how they …

cancer
proctectomy
rectal cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location